Stifel Nicolaus cut shares of Clinigen Group (OTCMKTS:CLIGF) from a buy rating to a hold rating in a research note released on Thursday morning, The Fly reports.
Separately, Zacks Investment Research upgraded Clinigen Group from a sell rating to a hold rating in a research note on Wednesday, June 2nd.
Shares of CLIGF opened at $11.56 on Thursday. Clinigen Group has a 12-month low of $11.56 and a 12-month high of $11.56. The company has a quick ratio of 1.33, a current ratio of 1.73 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 14.28 and a beta of 0.75. The firm’s 50-day moving average price is $9.01.
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines.
Featured Story: Trading Halts Explained
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.